These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7308554)

  • 1. Release of betamethasone 17-valerate from extemporaneous dilutions of a proprietary topical cream.
    Magnus AD; Haigh JM; Kanfer I
    Dermatologica; 1981; 163(4):331-7. PubMed ID: 7308554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of serial dilution of betamethasone-17-valerate on blanching potential and chemical stability.
    Ryatt KS; Cotterill JA; Mehta A
    J Clin Hosp Pharm; 1983 Jun; 8(2):143-5. PubMed ID: 6875011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The stability and blanching efficacy of betamethasone-17-valerate in emulsifying ointment.
    Ryatt KS; Feather JW; Mehta A; Dawson JB; Cotterill JA; Swallow R
    Br J Dermatol; 1982 Jul; 107(1):71-6. PubMed ID: 7104209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation factors affecting the isomerization rate of betamethasone-17-valerate in a developmental hydrophilic cream - a HPLC and microscopy based stability study.
    Byrne J; Wyraz A; Velasco-Torrijos T; Reinhardt R
    Pharm Dev Technol; 2017 Jun; 22(4):537-544. PubMed ID: 26895450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of some variables affecting the blanching activity of betamethasone 17-valerate cream.
    Magnus AD; Haigh JM; Kanfer I
    Dermatologica; 1980; 160(5):321-7. PubMed ID: 7364141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The stability and blanching efficiency of some Betnelan-V cream dilutions.
    Boonsaner P; Remon JP; De Rudder D
    J Clin Hosp Pharm; 1986 Apr; 11(2):101-6. PubMed ID: 3711358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible dosage regimens for topical steroids, assessed by vasoconstrictor assays using multiple applications.
    Woodford R; Haigh JM; Barry BW
    Dermatologica; 1983; 166(3):136-40. PubMed ID: 6852325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the bioactivity of mometasone furoate 0.1% fatty cream, betamethasone dipropionate 0.05% cream and betamethasone valerate 0.1% cream in humans. Inhibition of UV-B-induced inflammation monitored by laser Doppler blood flowmetry.
    Bjerring P
    Skin Pharmacol; 1993; 6(3):187-92. PubMed ID: 8274288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological evaluation of a new topical preparation containing dextran sulphate and betamethasone 17-valerate.
    Passarella E; Milanino R
    Arzneimittelforschung; 1980; 30(4):647-51. PubMed ID: 6156688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between in vivo skin blanching and in vitro release rate for betamethasone valerate creams.
    Shah VP; Elkins J; Skelly JP
    J Pharm Sci; 1992 Jan; 81(1):104-6. PubMed ID: 1619561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potency ranking of two new topical corticosteroid creams containing 0.1% desonide or 0.05% halometasone utilising the human skin blanching assay.
    Meyer E; Smith EW; Haigh JM; Kanfer I
    Arzneimittelforschung; 1988 Dec; 38(12):1840-3. PubMed ID: 3245859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palm Olein Emulsion: a Novel Vehicle for Topical Drug Delivery of Betamethasone 17-Valerate.
    Ahmad K; Win T; Jaffri JM; Edueng K; Taher M
    AAPS PharmSciTech; 2018 Jan; 19(1):371-383. PubMed ID: 28744617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The stability of betamethasone-17-valerate in semi-solid bases.
    Yip YW; Po LW
    J Pharm Pharmacol; 1979 Jun; 31(6):400-2. PubMed ID: 39141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blanching activities of betamethasone formulations. The effect of dosage form on topical drug availability.
    Smith EW; Meyer E; Haigh JM
    Arzneimittelforschung; 1990 May; 40(5):618-21. PubMed ID: 2383308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of bufexamac cream versus betamethasone valerate cream in contact dermatitis: a double-blind trial.
    Wolf-Jürgensen P
    Curr Med Res Opin; 1979; 5(10):779-84. PubMed ID: 373992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Onset of the vasoconstrictor effect of diflucortolone valerate, betamethasone valerate, and fluocinolone acetonide ointments applied for varying periods under occlusive dressings.
    Szadurski J; Renz F; Gasser D
    Dermatologica; 1976; 153(4):236-42. PubMed ID: 1017533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic effects of topical application of beclomethasone 17,21-dipropionate: comparative studies with betamethasone 17-valerate ointment and fluocinonide cream.
    Shimao S
    J Dermatol; 1979 Dec; 6(6):383-90. PubMed ID: 396316
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative blanching activities of proprietary diflucortolone valerate topical preparations.
    Coleman GL; Kanfer I; Haigh JM
    Dermatologica; 1978; 156(4):224-30. PubMed ID: 342295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind comparison of 1% hydrocortisone plus 10% urea ('Alphaderm') and 0.1% betamethasone 17-valerate in the treatment of non-infective inflammatory dermatoses.
    Khan SA; Williamson DM
    Curr Med Res Opin; 1977-1978; 5(4):354-8. PubMed ID: 343995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma concentrations of betamethasone after topical application of betamethasone 17-valerate: comparison with oral administration.
    Kubota K; Lo ES; Huttinot G; Andersen PH; Maibach HI
    Br J Clin Pharmacol; 1994 Jan; 37(1):86-8. PubMed ID: 8148226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.